Publications:

• Prevalence Of Androgen Receptor Positivity In Triple Negative Breast Cancer Martin P Jovita M*, Kalaichelvi Kannan and Kumar S Suresh Martin et al., J Integr Oncol 2018, 7:1
• A 20 years’ experience on granulosa cell tumour. P. Jovita M. Martin, Kalaichelvi K, Lakshminarasimhan, Ramkumar, Dheenadhayalan. Journal of Evolution of Medical and Dental sciences 2018;7(26):3004-3012
• Synchronous Malignancy A Rare Presentation of Double Primary in Female Genital Tract. Nanditha Srinivasan, Jovita Martin, Archana, Sai Shalini, Lakshmi Narasimhan, Manickavasagam Journal of Evolution Medical and Dental Sciences / Vol. 8/ Issue 51/ Dec. 23, 2019
• M. Kanchana, P.M.M. Jovita and M.G. Rajanandh, Drug-related problems and potentially inappropriate medications use in Indian geriatric patients receiving chemotherapy in the medical oncology unit of a tertiary care hospital Journal of Geriatric Oncology. JGO-01058; No. of pages: 4; 4C:
• Kunnuru SKR, Thiyagarajan M, Martin Daniel J, Singh K B. A Study on Clinical and Pathological Responses to Neoadjuvant Chemotherapy in Breast Carcinoma.  Breast Cancer (Dove Med Press). 2020;12:259-266  - https://doi.org/10.2147/BCTT.S277588 
• Sowmica Devabhaktuni1, P Jovita M. Martin Daniel1,2, Kumanan.J,Ravichandran Ambalathandi1,2Cancer Treatment during the Sars-Cov-2 Pandemic: Single Center Analysis. British Journal of Cancer Research 2020; 3(3): 401 - 406. doi: 10.31488/bjcr.156
• Kumanan.J1,P.Jovita.M.Martin Daniel2, Sowmica Devabhaktuni1, Manickavasagam Meenakshisundaram3.Tele Oncology Consultation During the Covid-19 Pandemic: Single Center Analysis . British Journal of Cancer Research 2020; 3(3):397 - 400. doi: 10.31488/bjcr.155
• Prescribing Pattern of Anticancer Drugs in a Medical Oncology Department of a Tertiary Care Teaching Hospital  Manichavasagam M, P Jovita M Martin, Lavanya R, Karthik S, Seenivasan P and Rajanandh MG*  Annals of Medical and Health Sciences Research July 25th 2017
• Prevalence Of Androgen Receptor Positivity In Triple Negative Breast Cancer Martin P Jovita M*, Kalaichelvi Kannan and Kumar S Suresh Martin et al., J Integr Oncol 2018, 7:1 
• An Uneventful Pregnancy and Delivery in a Metastatic Adult Wilms’ Tumor–A Rare Case Report MOJ Clinical and Medical case Reports Volume 7 Issue 4 2017.
• Multiple Primaries Rising Trend– a Case Series. P.Jovita M.Martin, Vijayasarathy.K.International journal of /medical Sciences and Health Research. Vol.01,Number 01,;2017 ISSN: 2581-3366
• Malignant Invasive Thymoma with chemotherapy alone. . P.Jovita M.Martin, Vijayasarathy.K., Vol.7,Issue 4, 2017
• Primary Intraspinal Primitive Neuro ectodermal tumor (PNET): A Rare Occurrence. Martin J (2017) MOJ Clin Med CASE Rep 7 (5): 00214

Research:

• Clinical Research Experience (at Sri Ramachandra Medical College and Hospital, Chennai)
• Trial Team In charge on Combined Modality Treatment Cancer Esophagus  Reference based on INT0123 and RTOG 94-05 Phase III.
• Sub-Investigator -A multinational randomized ,double blinded , placebo-controlled study to evaluate the efficacy and safety of AVE5026 in the prevention of venous thromboembolism (VTE) incancer patients at high risk for VTE and who are undergoing chemotherapy 2008 to 2010.
• Co-Investigator- A prospective ,non comparative ,open labeled,multicenter Post Marketing Safety Surveillance study to evaluate the safety and immunogenicity of neukine in clinical practice 2008 to 2009.
• Co-Investigator-A phase I/II study to evaluate safety and efficacy of P276-00 in combination with Gemcitabine in patients with cancer of pancreas . 
• Co-Investigator-A phase III open label extension trial of the safety  and efficacy of ferumoxytol for episodic treatment of Iron deficiency anaemia.
•  Co-Investigator- Predictive factors in Stomach Cancers Evaluation of Polymorphisms in Thymidilate synthase gene as markers for response to 5-Fluorouracil based treatment regimen in Gastric Cancer in an Indian Population (awaiting sanction for funding ICMR) 
• Ongoing trials
• Principle Investigator:  Protocol No: GBR 200-301 ‘’A Prospective , Multicentre , Randomized , Double – blind , Parallel- Group study to compare the efficacy and safety of GBR 200 (similar biologic of trastuzumab ) versus innovator trastuzumab both given in combination with paclitaxel in patients diagnosed with HER2 positive Metastatic breast cancer .
• Principle Investigator:  BCD-021-02 ‘’ International multicentre randomized double blind phase III trial comparing safet) and efficacy of BCD-021 (CJSC BIOCAD, Russia ) and paclitaxel   +  carboplatin to Avastin ( F. Hoffmann – La  Roche LTD , Switzerland ) and paclitaxel   +  carboplatin in inoperable or advanced non- squamous non- small – cell lung cancer patients. ‘’
• Principle Investigator A Randomised open labelled two arm, single dose, cross over, bioequilence study of Ayana pharma Doxorubicin Hydrochloride Liposome injection , Sun pharma in subjects with ovarian cancer

Academic:

• Dr. P. Jovita M. Martin delivered a guest lecture on “Cancer Awareness” at ASCENDAS, IT Park to the AMEC Foster wheeler on 22 nd March 2018 at attended one day workshop on “Electro-Chemo Therapy for Effective Cancer Treatment” held on 14 th March 2018 at BS Abdur Rahman Crescent Institute of Science and Technology, Vandalur, Chennai.
• Dr. Jovita Martin as Speaker at Mumbai in Best of MASCC on September 1 st 2018 Topic Oncological Emergencies in Palliative care.
• Dr. Jovita Martin as Panelist in Multiple Myeloma at Madurai 10 th November 2018
• Dr.Jovita Martin as speaker at Chicago 27 th World Oncologists Conference.Topic .A 20 years’ experience on granulosa cell tumour on Dec 7 th 2018.

Other Information:

Interests 

The Oncological case burden has increased to a large extent compare to yester years .My current clinical and research interests lie in the management of Breast cancers, Gynecological cancers, Genito urinary malignancies and Pediatric malignancies. I also have an interest in lymphomas, soft tissue sarcomas, and Head & Neck Cancers. I believe advances in molecular imaging, particularly detection of oligometastases, targeting therapy and monitoring of treatment response, will have a significant impact in our field. I have also been interested on the role of influence of Geo chemistry (water , soil, air, apart from habits and occupation and Genetics ) in its contribution , influence and impact on Cancer.